Abstract
Background
Malignant hyperthermia (MH) is a disorder of calcium homeostasis in skeletal muscle triggered by volatile anesthetics or succinylcholine in susceptible persons. More than 100 mutations in the ryanodine receptor type 1 gene (RYR1) have been associated with MH susceptibility, central core disease, or both. RYR1 mutations may account for up to 70% of MH-susceptible cases. The authors aimed to determine the frequency and distribution of RYR1 mutations in the Japanese MH-susceptible population.Methods
The authors selected 58 unrelated Japanese diagnosed as MH-susceptible for having an enhanced Ca-induced Ca release rate from the sarcoplasmic reticulum on chemically skinned muscle fibers. They sequenced the entire RYR1 coding region from genomic DNA. Muscle pathology was also characterized.Results
Seven previously reported and 26 unknown RYR1 potentially pathogenic sequence variations were identified in 33 patients (56.9%). Of these patients, 48% had cores on muscle biopsy. The mutation detection rate was higher in patients with clear enhancement of Ca-induced Ca release rate (72.4%), whereas all patients with central core disease had RYR1 mutations. Six patients harbored potentially causative compound heterozygous sequence variations.Conclusions
Distribution and frequency of RYR1 mutations differed markedly from those of the North American and European MH-susceptible population. Comprehensive screening of the RYR1 gene is recommended for molecular investigations in MH-susceptible individuals, because many mutations are located outside the "hot spots." Based on the observed occurrence of compound heterozygous state, the prevalence of a possibly predisposing phenotype in the Japanese population might be as high as 1 in 2,000 people.References
Articles referenced by this article (44)
Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders.
Neuromuscul Disord, (9-10):577-587 2005
MED: 16084090
Ryanodine receptor defects in muscle genetic diseases.
Biochem Biophys Res Commun, (4):1245-1255 2004
MED: 15336972
Ryanodine receptor mutations in malignant hyperthermia and central core disease.
Hum Mutat, (5):410-417 2000
MED: 10790202
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.
Curr Mol Med, (4):347-369 2002
MED: 12108947
Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
Anesth Analg, (4):511-515 1989
MED: 2675676
In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Acta Anaesthesiol Scand, (8):955-966 1997
MED: 9311391
Title not supplied
Biomed Res 1983
Title not supplied
1987
Show 10 more references (10 of 44)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/115037750
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1097/00000542-200606000-00008
Article citations
Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative review.
Br J Anaesth, 133(4):759-767, 05 Aug 2024
Cited by: 0 articles | PMID: 39107166 | PMCID: PMC11443134
Review Free full text in Europe PMC
Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants.
Genes (Basel), 14(11):2009, 27 Oct 2023
Cited by: 1 article | PMID: 38002952
Variant landscape of the RYR1 gene based on whole genome sequencing of the Singaporean population.
Sci Rep, 12(1):5429, 31 Mar 2022
Cited by: 2 articles | PMID: 35361824 | PMCID: PMC8971428
A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course.
Acta Neuropathol Commun, 9(1):155, 17 Sep 2021
Cited by: 3 articles | PMID: 34535181 | PMCID: PMC8447513
A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.
Nat Commun, 12(1):4293, 13 Jul 2021
Cited by: 16 articles | PMID: 34257294 | PMCID: PMC8277899
Go to all (66) article citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.
Anesthesiology, 102(3):515-521, 01 Mar 2005
Cited by: 81 articles | PMID: 15731587
North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
Anesthesiology, 95(3):594-599, 01 Sep 2001
Cited by: 25 articles | PMID: 11575529
Ryanodine receptor mutations in malignant hyperthermia and central core disease.
Hum Mutat, 15(5):410-417, 01 Jan 2000
Cited by: 200 articles | PMID: 10790202
Review
RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Hum Mutat, 20(2):88-97, 01 Aug 2002
Cited by: 49 articles | PMID: 12124989